Identification of VP22 as an antagonist of type I interferon response in pseudorabies virus, suggesting a novel mechanism against cGAS activation.
Cyclic GMP-AMP synthase (cGAS) is a pivotal DNA sensor that initiates antiviral responses, yet the mechanisms by which viruses evade cGAS-mediated innate immunity remain poorly understood. Here, we identified VP22, a tegument protein of pseudorabies virus (PRV), a member of the Alphaherpesvirinae subfamily, as a viral antagonist of the type I interferon (IFN-I) response through hijacking the host RNA helicase DDX21. Specifically, VP22 impairs 2’3’-cyclic GMP–AMP (cGAMP) synthesis by disrupting cGAS condensation. In vivo, cGAS restricts the replication of VP22-deficient PRV and attenuates its pathogenicity, an effect neutralized by VP22. Notably, DDX21 is essential for VP22-mediated inhibition of cGAS activity. Mechanistically, VP22 stabilizes DDX21 protein level and enhances its interaction with cGAS. Furthermore, VP22 promotes the translocation of DDX21 from the nucleus to the cytoplasm, a process required for inhibition of cGAS condensation and activation. Collectively, these findings reveal a previously unrecognized, host-dependent mechanism by which PRV subverts cGAS signaling, shedding light on viral strategies to subvert host DNA sensing and innate immunity.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: